Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15554326 | 0.79 | ALDH1A1 (0.39) | TDP1CNR2PLA2G2ASMN1; SMN2TSHR | |
| SCHEMBL1821906 | 0.77 | CNR2 (0.47) | TDP1CNR2PLA2G2ASMN1; SMN2TSHR | |
| SCHEMBL3690830 | 0.77 | MCL1 (0.39) | TDP1CNR2PLA2G2ASMN1; SMN2TSHR | |
| SCHEMBL3686582 | 0.72 | TDP1 (0.39) | TDP1PLA2G2ASMN1; SMN2TSHRGPR35 | |
| SCHEMBL3690450 | 0.71 | GAA (0.49) | TDP1SMN1; SMN2TSHRGPR35ALDH1A1 | |
| SCHEMBL16079468 | 0.70 | HTR6 (0.60) | HTR2AHTR2C | |
| SCHEMBL15826054 | 0.69 | PDE10A (0.44) | TDP1SMN1; SMN2ALDH1A1POLBMET | |
| SCHEMBL19869857 | 0.68 | GAA (0.56) | TDP1SMN1; SMN2TSHRALDH1A1MAPT | |
| SCHEMBL14981597 | 0.68 | TDP1 (0.47) | TDP1PLA2G2ASMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL26630271 | 0.68 | MAPT (0.56) | TDP1CNR2SMN1; SMN2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| CN-101917999-A | Modulation of protein trafficking | FOLDRX PHARMACEUTICALS INC | 2010-12-15 | — | — | CN | disclosed |
| US-20100273776-A1 | INHIBITION OF ALPHA-SYNUCLEIN TOXICITY | FOLDRx PHARMACEUTICALS, INC (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273776-A1 | INHIBITION OF ALPHA-SYNUCLEIN TOXICITY | FOLDRx PHARMACEUTICALS, INC (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273776-A1 | INHIBITION OF ALPHA-SYNUCLEIN TOXICITY | FOLDRx PHARMACEUTICALS, INC (US) | 2010-10-28 | — | — | US | disclosed |
| EP-2217239-A2 | MODULATION OF PROTEIN TRAFFICKING | Foldrx Pharmaceuticals, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| CN-101460161-A | Inhibition of alpha-synuclein toxicity | FOLDRX PHARMACEUTICALS INC (US) | 2009-06-17 | — | — | CN | disclosed |
| WO-2009062118-A2 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| EP-2007373-A2 | INHIBITION OF ALPHA-SYNUCLEIN TOXICITY | Foldrx Pharmaceuticals, Inc. (US) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007126841-A2 | INHIBITION OF ALPHA-SYNUCLEIN TOXICITY | FOLDRX PHARMACEUTICALS, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007126841-A2 | INHIBITION OF ALPHA-SYNUCLEIN TOXICITY | FOLDRX PHARMACEUTICALS, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273776-A1 | INHIBITION OF ALPHA-SYNUCLEIN TOXICITY | SNCA, PARK7, PINK1 | TDP1 356/4885CNR2 4273/4885PLA2G2A 2982/4885 |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | RAB1A, COPB1, GOLT1B | TDP1 3089/4885CNR2 3822/4885PLA2G2A 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.